» Articles » PMID: 27823976

Dysregulation of Macrophage Polarization is Associated with the Metastatic Process in Osteosarcoma

Overview
Journal Oncotarget
Specialty Oncology
Date 2016 Nov 9
PMID 27823976
Citations 92
Authors
Affiliations
Soon will be listed here.
Abstract

Osteosarcoma (OS) is the most common bone sarcoma in adolescents, and has poor prognosis. A vicious cycle is established between OS cells and their microenvironment in order to facilitate the tumor growth and cell spreading. The present work aims to better characterize the tumor microenvironment in OS in order to identify new therapeutic targets relating to metastatic process. Tissue microarrays of pre-chemotherapy OS biopsies were used for characterizing the tumor niche by immunohistochemistry. Parameters studies included: immune cells (M1, M2-subtypes of tumor-associated macrophages (TAM); T, B lymphocytes; mast cells), vascularization (endothelial, perivascular cells), OPG, RANKL, and mitotic index. Two groups of patients were defined, 22 localized OS (OS Meta-) and 28 metastatic OS (OS Meta+). The OS Meta- group was characterized by a higher infiltration of INOS+ M1-polarizedmacrophages and upregulated OPG immunostaining. OS Meta+ tumors showed a significant increase in CD146+ cells. INOS+ M1-macrophages were correlated with OPG staining, and negatively with the presence of metastases. CD163+ M2-macrophages were positively correlated with CD146+ cells. In multivariate analysis, INOS and OPG were predictive factors for metastasis. An older age, non-metastatic tumor, good response to chemotherapy, and higher macrophage infiltration were significantly associated with better overall survival. TAMs are associated with better overall survival and a dysregulation of M1/M2 polarized-macrophages in favor of M1 subtype was observed in non-metastatic OS.

Citing Articles

Exosome tropism and various pathways in lung cancer metastasis.

Chen H, Liu L, Xing G, Zhang D, A N, Huang J Front Immunol. 2025; 16:1517495.

PMID: 40028322 PMC: 11868168. DOI: 10.3389/fimmu.2025.1517495.


Progress in immune microenvironment, immunotherapy and prognostic biomarkers in pediatric osteosarcoma.

Zhang L, Jiang H, Ma H Front Immunol. 2025; 16:1548527.

PMID: 39911380 PMC: 11794274. DOI: 10.3389/fimmu.2025.1548527.


Comprehensive analysis of ESCRT transcriptome-associated signatures and identification of the regulatory role of LMO7-AS1 in osteosarcoma.

Zhao S, Tian D, Huang F, Wang L, Cheng J, He Z Cancer Cell Int. 2025; 25(1):29.

PMID: 39885569 PMC: 11783933. DOI: 10.1186/s12935-025-03659-4.


Osteosarcoma tumor microenvironment: the key for the successful development of biologically relevant 3D in vitro models.

Rodrigues J, Sarmento B, Leite Pereira C In Vitro Model. 2025; 1(1):5-27.

PMID: 39872973 PMC: 11756501. DOI: 10.1007/s44164-022-00008-x.


A detoxified TLR4 agonist inhibits tumour growth and lung metastasis of osteosarcoma by promoting CD8+ cytotoxic lymphocyte infiltration.

Oyama R, Nabeshima A, Endo M, Novikov A, Fujiwara T, Phelip C BJC Rep. 2025; 3(1):5.

PMID: 39870886 PMC: 11772650. DOI: 10.1038/s44276-024-00120-3.


References
1.
Ando K, Mori K, Corradini N, Redini F, Heymann D . Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother. 2011; 12(2):285-92. PMC: 3413631. DOI: 10.1517/14656566.2011.543129. View

2.
Mosheimer B, Kaneider N, Feistritzer C, Djanani A, Sturn D, Patsch J . Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab. 2005; 90(5):2964-71. DOI: 10.1210/jc.2004-1895. View

3.
Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

4.
Mohseny A, Hogendoorn P . Concise review: mesenchymal tumors: when stem cells go mad. Stem Cells. 2011; 29(3):397-403. DOI: 10.1002/stem.596. View

5.
Guo C, Buranych A, Sarkar D, Fisher P, Wang X . The role of tumor-associated macrophages in tumor vascularization. Vasc Cell. 2013; 5(1):20. PMC: 3913793. DOI: 10.1186/2045-824X-5-20. View